RESUMEN
UNLABELLED: To evaluate clinical implications of the serum level of soluable receptors of tumor necrosis factor alpha (TNFa) with molecular mass 55 kDa (rTNF-55R) in rheumatoid arthritis, serum levels of rTNF-55R and rTNF-75R were measured with the use of radioimmunoassay in 76 RA patients, 38 donors and in 25 RA patients, 10 donors, respectively. RESULTS: Elevated serum level of rTNF-55R was recorded in 55.3% RA patients. This level correlated with basic clinical and laboratory parameters of RA, the disease activity, values of DAS indices. It is concluded that a serum level of rTNF-55R adequately reflects clinico-laboratory activity of RA and its measurement can be used for assessment of RA activity and treatment efficiency.
Asunto(s)
Antígenos CD/metabolismo , Artritis Reumatoide/metabolismo , Artritis Reumatoide/fisiopatología , Inmunoglobulina G/metabolismo , Receptores del Factor de Necrosis Tumoral/metabolismo , Adolescente , Adulto , Anciano , Etanercept , Femenino , Humanos , Masculino , Persona de Mediana Edad , Peso Molecular , Receptores Tipo I de Factores de Necrosis Tumoral , Índice de Severidad de la Enfermedad , Factores de TiempoRESUMEN
AIM: To compare domestic criteria of RA activity and the disease activity scores (DAS). MATERIAL AND METHODS: Russian criteria of RA activity and DAS were used in 99 RA patients. RESULTS: It is shown that RA activity by DAS is higher than when it is assessed by criteria practiced in Russia. CONCLUSION: Further studies are necessary to examine clinical value of DAS criteria.
Asunto(s)
Artritis Reumatoide/diagnóstico , Humanos , Índice de Severidad de la EnfermedadRESUMEN
The serum level of soluble TNF-alpha receptors with molecular mass 55 kDa (sTNF-a55R) was measured by enzyme immunoassay with commercial kits in 30 patients with rheumatoid arthritis (RA) and 38 healthy donors. High sTNF-a55R serum levels were registered in 90% of RA patients. These levels correlated with RA activity by DAS. Thus, assay for sTNF-a55R can be used for assessing RA activity.
Asunto(s)
Artritis Reumatoide/sangre , Receptores del Factor de Necrosis Tumoral/sangre , Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Etanercept , Femenino , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina G/uso terapéutico , Masculino , Persona de Mediana Edad , Receptores del Factor de Necrosis Tumoral/uso terapéuticoRESUMEN
AIM: To evaluate effectiveness and tolerance of subreum in early rheumatoid arthritis (RA). MATERIAL AND METHODS: 44 patients with early rheumatoid arthritis. Subreum was given as a single drug and in combination with other basic drugs. Tolerance was evaluated in all the examinees, the effect--in 13 patients who finished the 6-month treatment by the articular syndrome, by ACR, DAS and HAQ criteria. RESULTS: By DAS, a good response was achieved in 2 patients (15%), a satisfactory one--in 3 (23%) patients. By ACR criteria, a 20% and 50% improvement was obtained in 3 (23%) and 4 (31%) patients. Side effects were absent in 41 (93%) patients. CONCLUSION: Subreum proved effective and well tolerable in early RA.
